FLSmidth A/S
FLSmidth & Co. A/S financial calendar for 2026
FLSmidth & Co. A/S financial calendar for 2026
COMPANY ANNOUNCEMENT NO. 43-2025
FLSmidth & Co. A/S
12 November 2025
Copenhagen, Denmark
For the year 2026, FLSmidth has planned the following dates for the release of financial reports and the annual general meeting:
- 18 February 2026: 2025 Annual Report
- 24 March 2026: Annual General Meeting
- 13 May 2026: Q1 2026 Interim Financial Report
- 19 August 2026: H1 2026 Interim Financial Report
- 11 November 2026: Q3 2026 Interim Financial Report
Contacts:
Investor Relations
Andreas Holkjær, +45 24 85 03 84, andh@flsmidth.com
Jannick Denholt, +45 21 69 66 57, jli@flsmidth.com
Media
Jannick Denholt, +45 21 69 66 57, jli@flsmidth.com
About FLSmidth
FLSmidth is a full flowsheet technology and service supplier to the global mining industry. We enable our customers to improve performance, lower operating costs and reduce environmental impact. MissionZero is our sustainability ambition towards zero emissions in mining by 2030. We work within fully validated Science-Based Targets, have a clear commitment to improving the sustainability performance of the global mining industry and aim to become carbon neutral in our own operations by 2030. www.fls.com
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
DP World12.11.2025 15:00:00 CET | Press release
DP World Moves 60% of Peru’s Avocado Exports Through the Port of Callao
Accumulus Technologies12.11.2025 15:00:00 CET | Press release
Accumulus Technologies Appoints Mervyn Hall as Chief Commercial Officer
iHerb Holdings, Inc.12.11.2025 15:00:00 CET | Press release
iHerb Kicks Off Global Gifting Season with its Annual Black Friday and Cyber Monday Sales Event
BYD12.11.2025 14:49:09 CET | Press release
BYD delivers the new SEALION 7 INTER EDITION to FC Internazionale Milano
Chiesi Group12.11.2025 14:30:00 CET | Press release
Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom